Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients.

Georgios NteliopoulosKaren PageAllison HillsKaren HowarthWarren EmmettEmma GreenLuke J MartinsonDaniel Fernadez-GarciaRobert HastingsDavid S GutteryLaura KennyJustin StebbingSusan CleatorFarah RehmanKelly L T GleasonAndrijac SanelaCharlotte IonAmelia J RushtonNitzan RosenfeldR Charles CoombesJacqueline A Shaw

Published in: Breast cancer research and treatment (2021)

This study shows that both ultra-deep next-generation sequencing (NGS) technologies can detect genomic alternations even at low VAFs in plasma samples of mBC patients. The strong agreement of the technologies indicates sufficient reproducibility for clinical use as prognosic and predictive biomarker.

Keyphrases

end stage renal disease
high resolution
circulating tumor
ejection fraction
chronic kidney disease
copy number
newly diagnosed
prognostic factors
peritoneal dialysis
stem cells
cell free
single cell
drug delivery
bone marrow
gene expression